Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider
[see
Boxed Warningand Warnings and Precautions (
5.1)]
.
Dosage and Administration
Instruct patients to take vilazodone hydrochloride tablets with food and to follow prescribed dosage instructions
[see Dosage and Administration (
2.1,
2.3,
2.4,
2.5)]
.
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of vilazodone hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Patients should contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome
[see Warnings and Precautions (
5.2) and Drug Interactions (
7)]
.
Increased Risk of Bleeding
Inform patients about the concomitant use of vilazodone hydrochloride tablets with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use of drugs that interfere with serotonin reuptake (e.g., vilazodone hydrochloride) and these medications has been associated with an increased risk of bleeding. Advise them to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding
[see Warnings and Precautions (
5.3)]
.
Activation of Mania/Hypomania
Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider
[see Warnings and Precautions (
5.4)]
.
Discontinuation Syndrome
Advise patients not to abruptly discontinue vilazodone hydrochloride tablets and to discuss any tapering regimen with their healthcare provider. Adverse reactions can occur when vilazodone hydrochloride tablets are discontinued
[see Warnings and Precautions (
5.5)]
.
Seizures
Caution patients about using vilazodone hydrochloride tablets if they have a history of a seizure disorder
[see Warnings and Precautions (
5.6)].
Sexual Dysfunction
Advise patients that use of vilazodone hydrochloride tablets may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider
[see Warnings and Precautions (
5.9)].
Allergic Reactions
Advise patients to notify their healthcare provider if they develop an allergic reaction such as rash, hives, swelling, or difficulty breathing
[see Adverse Reactions(
6.2)].
Concomitant Medications
Advise patients to inform their health care providers if they are taking, or plan to take any prescription or over-the-counter medications since there is a potential for interactions
[see Drug Interactions (
7.1)]
.
Pregnancy
- Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with vilazodone hydrochloride
[see Use in Specific Populations (
8.1)]
.
- Advise patients that vilazodone hydrochloride use late in pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN)
[see Use in Specific Populations (
8.1)]
.
- Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to vilazodone hydrochloride during pregnancy
[see Use in Specific Populations (
8.1)]
.
Medication guide available at
www.accordhealthcare.us/medication-guides
All trademarks are the property of their respective owners.
Manufactured for:
Accord Healthcare, Inc.,
8041 Arco Corporate Drive,
Suite 200,
Raleigh, NC 27617,
USA.
Manufactured by:
Intas Pharmaceuticals Limited,
Plot No.: 457, 458,
Village – Matoda,
Bavla Road, Ta. – Sanand,
Dist.- Ahmedabad – 382 210,
INDIA
10 5678 2 6024023
Issued June 2024